Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00446303
Status:
TERMINATED
Last Update Posted:
2012-01-19
First Post:
2007-03-09
Brief Title:
A Phase II Study of Maintenance With Azacitidine in MDS Patients
Sponsor:
Groupe Francophone des Myelodysplasies
Organization:
Groupe Francophone des Myelodysplasies
Study Overview
Official Title:
A Phase II Study of Maintenance With Azacitidine in MDS Patients Achieving Complete or Partial Remission CR or PR After Intensive Chemotherapy
Status:
TERMINATED
Status Verified Date:
2010-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase II multicentre trial of maintenance with Azacitidine in MDS patients achieving complete or partial remission CR or PR after intensive chemoterapy
The primary objective is response duration MDS or AML
The primary objective is response duration MDS or AML
Detailed Description:
A academic multicentre study whose aims are to study the benefits of a maintenance therapy with 24 monthly courses af azacytidine in high-risk MDS patients previously treated with intensive chemotherapy with obtention of a partial or complete response and not eligible for allogeneic transplantation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None